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Abstract
The incidence of malignant melanoma has rapidly increased in recent years. Evidence points to the
role of inheritance in melanoma development, but specific genetic risk factors are not well
understood. Recent reports indicate a high prevalence of somatic mutations of the BRAF gene in
melanomas and melanocytic nevi. Here we report that germ-line single nucleotide polymorphisms
(SNPs) in BRAF are significantly associated with melanoma in German males, but not females. At-
risk haplotypes of BRAF are shown. Based upon their frequencies, we estimate that BRAF could
account for a proportion attributable risk of developing melanoma of 4% in the German population.
The causal variant has yet to be determined. The burden of disease associated with this variant is
greater than that associated with the major melanoma susceptibility locus CDKN2A, which has an
estimated attributable risk of less than 1%.
Introduction
Melanoma is an aggressive skin cancer which, once metas-
tasized, is resistant to most current treatments. Malignant
melanoma is the leading cause of death from skin dis-
eases, and its mortality rate is increasing faster than for
any other malignant disease except lung cancer [1]. In
2002, 53,600 new cases of melanoma were projected for
the U.S.: 30,100 in males and 23,500 in females [2]. The
lifetime probability of developing melanoma is 1.72% for
males and 1.22% for females, and older males have dou-
ble the prevalence compared with older females [2,3].
Familial melanoma represents 8–12% of all melanoma
cases. Germ-line mutations in CDKN2A also called p16-
gene [4,5] and CDK4 [6] have been identified in different
proportions ranging from 5% to approximately 90% in
monogenic melanoma patients [7]. Sporadic malignant
melanoma accounts for the vast majority, i.e. about 90%
of cases, and genetic factors that mediate susceptibility to
this form of melanoma are not well understood. Several
candidate genes have been reported to predispose to spo-
radic melanoma, including vitamin D receptor (VDR;
MIM# 601769) [8], the melanocyte-stimulating hormone
receptor (MC1R; MIM# 155555) [9,10], glutathione-S-
transferase M1 (GSTM1; MIM# 138350) [11], a gene of
the cytochrome P450 family (CYP2D6; MIM# 124030)
[12], as well as epidermal growth factor (EGF; MIM#
131530) [13]. The hitherto best known melanoma risk
factor  CDKN2A  accounts for about 25% of familial
melanoma cases [14], but less than 1% of all melanoma
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cases [15,16]. The etiology of sporadic melanoma is com-
plex and likely involves interactions of multiple low-pen-
etrance susceptibility genes, the influences of
environmental exposures such as ultraviolet (UV) light,
and the interaction of genotype and environment.
Recently, single nucleotide polymorphisms (SNPs) have
emerged as markers of choice for complex disease gene
mapping because of their high density and even distribu-
tion across the human genome [17]. Feasibility studies to
establish the strategies and methodologies of SNP use
now allow direct comparison of allele frequencies in case-
control populations using DNA pools [18,19].
Analysis and Results
Genome-Wide Association Study
To screen for major genetic factors contributing to the
development of melanoma, we conducted a genome-wide
SNP association study to systematically compare allele fre-
quencies of approximately 25,133 SNPs in a melanoma
case-control cohort. The SNP set covers 15,275 human
genes that account for approximately 46% of the entire
human genome. Frequencies of the minor allele of the
SNPs analysed were at least 10%, with a median spacing
of 38 kb and a mean spacing of 120 kb [20]. Initial results
of this genome scan indicated a significant association of
a SNP located in the BRAF gene with the disease in male
melanoma patients. To further evaluate this, we pro-
ceeded with direct analysis of the BRAF gene.
BRAF Gene Analysis
Four non-coding SNPs (BRAF-1, BRAF-2, BRAF-3, BRAF-
4) in the BRAF gene region were tested (Table 1). The
allele frequency of BRAF-1, a SNP located in intron 11 of
BRAF, was significantly different between male cases and
control groups (p = 0.045). This corresponded to a male
genotypic relative risk of 1.67 (multiplicative penetrance
model; 95% confidence interval, 1.03–2.78). The fre-
quency of BRAF-3, a further non-coding SNP, showed bor-
derline significance (p = 0.078) in the male study
population (Table 1), while BRAF-2 and BRAF-4 frequen-
cies were not associated with melanoma risk.
Haplotype analysis of these four SNPs by the D' and r2
tests indicated that they were in strong linkage disequilib-
rium (LD). Eight haplotypes were identified for these four
SNPs, three of which accounted for approximately 98% of
all haplotype combinations (Table 2). Comparison of
haplotype frequencies in affected and control groups
showed significant differences between male case and
control groups, as well as between the combined case and
control groups (Table 3). Haplotype-based genotype data
(Table 3) were analysed using a standard chi-square test of
Table 1: Allele frequencies of SNPs in the BRAF gene in the German cohort. Location of SNPs within BRAF and refSNP Ids are listed.
SNP Id. dbSNP rs# Exon/Intron* M case M control p-value F case F control p-value
BRAF-1 rs1639679 Intron 11 C = 0.888 C = 0.927 0.045 C = 0.943 C = 0.934 0.585
A = 0.112 A = 0.073 A = 0.057 A = 0.066
BRAF-2 rs1267646 Intron 9 C = 0.839 C = 0.870 0.240 C = 0.870 C = 0.867 0.914
T = 0.161 T = 0.130 T = 0.130 T = 0.133
BRAF-3 rs1267606 Intron 2 T = 0.890 T = 0.925 0.078 T = 0.942 T = 0.930 0.477
G = 0.110 G = 0.075 G = 0.057 G = 0.070
BRAF-4 rs1267621 Intron 1 G = 0.839 G = 0.873 0.147 G = 0.868 G = 0.880 0.584
A = 0.171 A = 0.127 A = 0.132 A = 0.120
BRAF-5 rs1267601 Intron 2 A = 0.894 A = 0.932 0.041 A = 0.944 A = 0.935 0.526
G = 0.106 G = 0.068 G = 0.056 G = 0.065
BRAF-6 rs1267609 Intron 3 C = 0.882 C = 0.907 0.008 C = 0.945 C = 0.935 0.539
T = 0.118 T = 0.093 T = 0.055 T = 0.065
BRAF-7 rs1267636 Intron 8 A = 0.891 A = 0.939 0.010 A = 0.945 A = 0.935 0.517
G = 0.109 G = 0.061 G = 0.055 G = 0.065
BRAF-8 rs1267649 Intron 5 G = 0.896 G = 0.934 0.038 G = 0.945 G = 0.934 0.474
C = 0.104 C = 0.066 C = 0.055 C = 0.066
BRAF-9 rs1639675 Intron 7 A = 0.891 A = 0.930 0.041 A = 0.945 A = 0.939 0.719
G = 0.109 G = 0.070 G = 0.055 G = 0.061
BRAF-10 rs1267610 Intron 3 G = 0.732 G = 0.770 0.187 G = 0.766 G = 0.784 0.507
A = 0.268 A = 0.230 A = 0.234 A = 0.216
BRAF-11 rs1267625 Intron 2 T = 0.833 T = 0.870 0.135 T = 0.872 T = 0.864 0.716
G = 0.167 G = 0.130 G = 0.128 G = 0.136
BRAF-12 rs1267618 Intron 1 G = 0.837 G = 0.871 0.146 G = 0.868 G = 0.867 0.961
A = 0.163 A = 0.129 A = 0.132 A = 0.133
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independence. This analysis demonstrated that the haplo-
type CTTG (H4) was significantly associated with melon-
oma in both males and the total melanoma case cohort,
but not for female case patients when analysed separately.
ATGA (H2) was significantly associated with melanoma
in males only. The frequency of the most common haplo-
type, CCTG (H1), did not differ significantly between
cases and controls in any group.
We subsequently genotyped eight additional non-coding
SNPs (BRAF-5 to BRAF-12) in this region. Five additional
SNPs (BRAF-5 to BRAF-9) showed significant frequency
differences between cases and controls in the male study
populations. None of the 12 SNPs genotyped showed any
significant association in female melanoma patients
(Table 1).
Discussion
BRAF (MIM# 164757) encodes a serine/threonine kinase
participating in the Ras/Raf/MAPK (mitogen-activated
protein kinase) signal transduction pathway [21]. The
BRAF gene is located on chromosome 7q34, and covers
approximately 190 kb. It contains at least 19 exons and
encodes a full-length transcript of 2,510 bp (NM_00433).
At least seven variant transcripts have been identified,
which are products of alternative splicing. From these var-
ious transcripts, several proteins are translated, including
the full-length, 94–95 kD, 783 amino acid product [22].
Recently, BRAF was found to be mutated in six of nine
(66%) primary malignant melanomas, with lower fre-
quencies of mutation ranging from 0.5% to 14% in other
primary tumours. Furthermore, 12 of 15 (80%)
melanoma short-term cultures and 20 of 34 (59%)
melanoma cell lines showed BRAF mutations. A single-
base substitution, which alters codon 599 (V599E) in
exon 15 of this gene, accounted for 35 (92%) of these 38
mutations observed. BRAF proteins with the V599E
substitution showed elevated kinase and transforming
activities compared to wildtype BRAF proteins [23].
Germline mutations of BRAF have not yet been detected
in familial or sporadic melanoma patients [24-26]. Anal-
ysis of 13 non-coding or silent BRAF polymorphisms did
not reveal significant frequency differences in 80 familial
or multiple melanoma cases compared to 91 cancer-free
controls [25].
Here, a genome-wide association study independently
pointed to BRAF as a gene associated with melanomas,
reinforcing the associations found in the previous studies.
Table 2: Haplotype frequencies of BRAF in our German cohort.
Haplotype SNP Frequency
BRAF-1 BRAF-2 BRAF-3 BRAF-4
H1 C C T G 0.843
H2 A T G A 0.074
H3 C T T A 0.064
H4 C T T G 0.012
H5 C C G G 0.003
H6 A C T G 0.002
H7 C C T A 0.002
H8 A C G A 0.001
Table 3: Haplotype analysis of the BRAF gene in our German case-control cohort.
Total Male Female
Haplotype Case
(N = 1000)
Control
(N = 898)
Case
(N = 470)
Control
(N = 434)
Case
(N = 530)
Control
(N = 464)
CCTG (H1) 84%(829) 86%(771) 81%(380) 86%(374) 85%(449) 86%(397)
ATGA (H2) 8%(82) 7%(59) p = 0.206 11%(52) 7%(30) p = 0.040 6%(30) 6%(29) p = 0.796
CTTA (H3) 6%(64) 6%(58) 5%(24) 6%(26) 8%(40) 7%(32)
CTTG (H4) 2%(20) 0%(3) χ2 = 16.75
p = 0.019
2%(11) 0%(2) χ2 = 15.85
p = 0.015
2%(9) 0%(1) χ2 = 7.82
p = 0.25
CCGG (H5) 0%(1) 0%(4) 0%(0) 0%(2) 0%(1) 0%(2)
ACTG (H6) 0%(1) 0%(2) 0%(0) 0%(0) 0%(1) 0%(2)
CCTA (H7) 0%(2) 0%(1) 0%(2) 0%(0) 0%(0) 0%(1)
ACGA (H8) 0%(1) 0%(0) 0%(1) 0%(0) 0%(0) 0%(0)Journal of Carcinogenesis 2003, 2 http://www.carcinogenesis.com/content/2/1/7
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On further evaluation, six non-coding SNPs and two com-
bined haplotypes were shown to confer a significantly
increased risk for developing melanoma in male patients
of German origin. Thus, aberrations of BRAF would seem
to cause disease predominantly in carrier males, which
correlates with the overall increased incidence of
melanoma in males as compared to females. A mecha-
nism to explain a possible sex-linked effect of BRAF is not
yet clear, and might be related to either genetic or environ-
mental factors.
Summary and Conclusion
In this report, we describe six SNPs and two haplotypes of
BRAF  significantly associated with melanoma in male
patients. One haplotype (H4) was also associated with an
increased melanoma risk for combined female and male
populations. Based on the observed genotype frequencies,
we estimate that BRAF could account for an attributable
risk of developing melanoma of approximately 4% in the
German population. This risk estimate is much higher
than that attributed to CDKN2A, whose contribution to
the population burden of melanoma is less than 1%. Our
results suggest that, in addition to the high somatic muta-
tion rate of BRAF in melanomas documented in previous
studies, germline polymorphisms in this gene predispose
males to melanoma. Thus, BRAF may be one explanation
of why males have an increased life-time incidence of
melanoma compared to females. Further studies, both in
German and other ethnic patient populations, will be nec-
essary to confirm a correlation between BRAF polymor-
phisms or haplotypes and disease. Additional
investigation is also needed to search for causal genetic
BRAF variants, possibly in 5' or 3' regions of this gene. Fur-
thermore, somatic mutations of BRAF have been observed
at high frequency (39%–69%) in papillary thyroid can-
cers [27-31], and to a lesser extent in lung [23,32,33] and
colorectal cancers [23,34-36]. It remains to be investigated
whether germline polymorphisms of BRAF also contrib-
ute to the risk of these common malignancies.
Methods
Clinical sample and phenotype collection
Blood samples were collected from caucasian Germans at
the Dermatology Department of the University Hospital
in Tuebingen, Germany. The study protocol was approved
by the local ethics committee and informed consent was
obtained from all individuals recruited. Case patients
were those diagnosed histologically with melanoma,
while controls were unrelated age-matched individuals
free of any cancer at the time of enrollment. A total of 236
male and 266 female patients diagnosed with cutaneous
malignant melanomas were enrolled with mean ages of
51 and 49, respectively. The control population consisted
of 217 males and 233 females with mean ages of 48 and
47, respectively.
DNA extraction and genotyping
DNA from 6–9 ml blood was extracted using a desalting
method (Gentra Systems, Minneapolis, MN, USA), and
quantitated using Pico green reagents and a Fluorometer
(Fluoroskan Ascent CF, Labsystems, Franklin, MA, USA).
All PCR and MassEXTEND reactions were conducted
using standard conditions as described previously [37].
Each reaction product was dispensed onto four silicon
chips and analyzed on a SEQUENOM-Bruker mass spec-
trometer (Sequenom Inc., San Diego, CA, USA). Spectra
were then analysed using SpectroTYPER™ software that
includes quantitative peak analysis functions for peak area
calculation and baseline correction. The corrected peak
areas for both alleles were used to calculate relative allele
frequencies.
Statistical Analysis
Haplotypes were reconstructed from SNP genotypes using
the statistical method developed by Stephens et al. [38],
and implemented in the PHASE computer program (ver-
sion 1.0). This method reconstructed a haplotype for each
genotyped individual. The extent of linkage disequilib-
rium (LD) between each pair of SNPs was estimated as the
difference between the observed two-locus haplotype fre-
quency using the major alleles at each SNP and the prod-
uct of the observed major allele frequencies. The LD
between SNPs was also expressed by two other common
standardized metrics, D' (D/min(p1q2, p2q1)) and r2 (D2/
p1p2q1q2), where p1 and q1 were the minor allele frequen-
cies at two SNPs, and p2 and q2 were the corresponding
major allele frequencies. Significant deviation of this dis-
equilibrium from zero was tested by the use of a chi-
square goodness-of-fit test.
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